Research and development of therapeutic mAbs: An analysis based on pipeline projects

Figures & data

Figure 1. Therapeutic categories of mAbs. Category of “others” includes eye diseases, respiratory diseases, metabolic diseases, etc.

Figure 2. Immunotherapeutic patterns of anti-cancer mAbs.

Figure 3. The trend and proportion of mAbs-related R&D over time.

Figure 4. Share of mAbs-related R&D programs at different pipeline phases. The designations of the phases of the projects are based not fully on definitions by regulatory authorities but on company definitions endorsed by IMS Health.

Table 1. Comparison of the share of mAb-related R&D programs at different pipeline phases across therapeutic areas

Pipeline status	Anti-cancer	Immunological	Anti-infective	Neuropharmacological	Cardiovascular and cerebrovascular	Others
Discovery	16%	13%	20%	21%	13%	26%
Preclinical	40%	32%	42%	48%	42%	24%
Phase I	10%	13%	4%	7%	7%	9%
Phase II	10%	12%	6%	10%	9%	16%
Phase III	2%	4%	1%	2%	6%	4%
Marketed	2%	4%	1%	0%	3%	2%
Discontinued	20%	22%	26%	13%	20%	19%

Figure 5. The top 25 organizations involved in mAb R&D.

Figure 6. Patent citation network of mAbs. Nodes represent patents; edges represent the citation relationship between patents. Different colors indicate patents associated with different therapeutic areas. Colors corresponding to the specific therapeutic areas mentioned above, with the exception of purple nodes, which represent patents in multiple therapeutic areas.